Stay updated on Nivolumab and Plinabulin in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Plinabulin in NSCLC Clinical Trial page.

Latest updates to the Nivolumab and Plinabulin in NSCLC Clinical Trial page
- ChecktodayChange DetectedRevision note updated from v3.3.3 to v3.3.4; no substantive study information appears to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a new Locations section showing California as a location (UC San Diego Moores Cancer Center). Removed the California Locations label and the HHS Vulnerability Disclosure, and updated the revision from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check50 days agoChange DetectedThe site revision was updated to v3.3.2 and v3.2.0 was removed; this is a minor metadata update that does not affect the study details or trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check57 days agoChange DetectedStudy status updated to Completed with updated completion date and last update timestamp; the page reflects the current state of the trial and its recent activity.SummaryDifference1.0%

- Check72 days agoChange Detected- The page shows minor editorial edits and a new last-updated timestamp; core study content, eligibility criteria, locations, and enrollment remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check86 days agoChange DetectedThe page updates primarily refresh date-related content (new dates added, old dates removed) and IPD planning labels, with no major changes to core content or pricing.SummaryDifference2%

Stay in the know with updates to Nivolumab and Plinabulin in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Plinabulin in NSCLC Clinical Trial page.